Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease

There currently is no specific antiviral drug or a vaccine for SARS-CoV-2/COVID-19 infections; now exceeding 10,300,000 infections worldwide. In the absence of animal models to test drugs, we need to find molecular explanations for any unforeseen peculiarities in clinical data, especially the recent...

Descripción completa

Detalles Bibliográficos
Autor principal: Cashman, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319607/
https://www.ncbi.nlm.nih.gov/pubmed/32758873
http://dx.doi.org/10.1016/j.mehy.2020.110027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319607/
https://www.ncbi.nlm.nih.gov/pubmed/32758873
http://dx.doi.org/10.1016/j.mehy.2020.110027

Ejemplares similares